A Phase 4 interventional study of dupilumab and Topical emollient (moisturizer) in Moderate-to-Severe Atopic Dermatitis and Atopic Eczema, sponsored by Regeneron Pharmaceuticals. Completed at 30 sites in United States. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2026-05-27.
Sponsored by Regeneron Pharmaceuticals · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 50 studies testing dupilumab in Dermatitis, Atopic — 4 open to participants now, 6 under way, none of them phase 3. dupilumab · Dermatitis, Atopic.
Among the 50 studies testing dupilumab in Dermatitis, Atopic, this one is the 23rd largest by enrollment, is one of 7 that started in 2023, is one of 24 in phase 4, and was the 40th registered.
1,594 studies on the registry are indexed under Dermatitis, Atopic; 287 are open to participants now.
Browse Dermatitis, Atopic studies →4 of the 50 studies testing dupilumab in Dermatitis, Atopic are open now, in 1 country. Recruiting first, the newest first:
Northwestern University · Sites in United States
Ages 6–17
University of California, San Francisco · Sites in United States
Ages 18+
University of Michigan · Sites in United States
Ages 18+
Sanofi
Ages 18+
By country, each count listing its studies:
dupilumab: first FDA approval 2017 (DUPIXENT), first EMA approval 2017. What it is approved for, and how studies give it, is on its page →
Of the 194 Dermatitis, Atopic studies recruiting now, 83 (43%) set no upper age limit and 95 (49%) stop at 75 or younger; 94 take children under 18; 51 take healthy volunteers.
This study: 12 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
On this site’s reading of the record, dupilumab is the treatment under test here. Read study by study →
50 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 8 · Phase 3 12 · Phase 4 24
First in 2011; this study’s year is marked. 7 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 124 is above the median of 82 across 1,248 interventional studies indexed under Dermatitis, Atopic.
Median enrollment 75 across the 50 interventional studies. Of the 38 that completed or were terminated, 26 (68%) have results posted.
This tab as a report to print or save as PDF → With an account.
32 of 50 have an industry lead sponsor. The 10 most frequent:
Regeneron Pharmaceuticals is the lead sponsor of 412 studies on the registry; 90 are open to participants now.
Of its 126 completed or terminated interventional studies of FDA-regulated products, 79 (63%) have results posted.
30 studies in Dermatitis, Atopic by Regeneron Pharmaceuticals: 1 open now, 2 under way, none of them phase 3. Of 27 finished, 18 (67%) have results posted.
Among the 30 studies in Dermatitis, Atopic by Regeneron Pharmaceuticals, this one is the 17th largest by enrollment of the 25 interventional ones that give a count, is the only one that started in 2023, is one of 2 in phase 4, and was the 28th registered.
Regeneron Pharmaceuticals’s Dermatitis, Atopic studies by the year they started, since 2011.
4 of the studies testing dupilumab in Dermatitis, Atopic that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07905547SanofiA Study to Investigate Dupixent/ Dupilumab in Adult Indian Participants With Moderate-to-severe Atopic Dermatitis | 2027-02-07 |
| NCT05983068SanofiA Study of Long-term Effect of Dupilumab on Skin Barrier Function in Pediatric Participants With Atopic Dermatitis | 2027-04-29 |
| NCT05042258Northwestern UniversityUsing Dupilumab to Improve Circadian Function, Sleep and Pruritus in Children With Moderate/Severe Atopic Dermatitis | 2027-06 |
| NCT05268107University of MichiganEthnic Differences in Mechanisms of Action of Dupilumab | 2027-07 |
Add all 4 to your calendar (.ics) → With an account.
Among the 50 studies testing dupilumab in Dermatitis, Atopic, from their registry updates:
Among Regeneron Pharmaceuticals’s 30 in Dermatitis, Atopic:
This tab as a report to print or save as PDF → With an account.
The study is focused on skin of color participants who have moderate-to-severe atopic dermatitis. Atopic dermatitis, also referred to as eczema, is a condition that causes the skin to become itchy, dry, and cracked.
From the previous studies on the study drug, it is seen that the study drug has an acceptable safety and effectiveness in participants with atopic dermatitis.
The aim of this study is to get additional information on the safety and effectiveness of the study drug, particularly the information on aspects of atopic dermatitis in skin of color participants.
The study is looking at several other research questions, including:
Key Inclusion Criteria:
Key Exclusion Criteria:
NOTE: Other Protocol Defined Inclusion / Exclusion Criteria Apply
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adolescents and adults will receive 1 of 2 dose regimens based on age and body weight
Drug: dupilumab · Other: Topical emollient (moisturizer)
Administered by subcutaneous (SC) injection once every 2 weeks (Q2W) following a loading dose
Also known as: Dupixent®, R668, SAR231893
Moisturizer should be applied twice daily, as per physician's recommendation, as defined in protocol.
Percentage of Participants With ≥75% Reduction From Baseline in Eczema Area and Severity Index (EASI) Score (EASI-75)
The EASI score was used to measure the severity and extent of atopic dermatitis (AD) and measures erythema, infiltration, excoriation and lichenification on 4 anatomic regions of the body: head, trunk, upper and lower extremities. The total EASI score ranges from 0 (minimum) to 72 (maximum) points, with the higher scores reflecting the worse severity of AD. EASI-75 responders were the participants who achieved ≥75% overall improvement in EASI score from baseline to Week 24.
Time frame: Week 24
Percentage of Participants With an Investigator's Global Assessment (IGA) Score 0 to 1
IGA is an assessment scale used to determine severity of atopic dermatitis (AD) and clinical response to treatment on a 5-point scale (0 = clear; 1 = almost clear; 2 = mild; 3 = moderate; 4 = severe) based on erythema and papulation/infiltration. Therapeutic response was an IGA score of 0 (clear) or 1 (almost clear). Percentage of participants with IGA "0" or "1" are reported at each visit.
Time frame: Weeks 2, 4, 8, 12, 16, 20, and 24
Percent Change From Baseline in EASI Score
The Eczema Area and Severity Index (EASI) score was used to measure the severity and extent of AD and measures erythema, infiltration, excoriation and lichenification on 4 anatomic regions of the body: head, trunk, upper and lower extremities. The total EASI score ranges from 0 (minimum) to 72 (maximum) points, with the higher scores reflecting the worse severity of AD.
Time frame: Weeks 2, 4, 8, 12, 16, 20, and 24
Change From Baseline in EASI Score
The Eczema Area and Severity Index (EASI) score was used to measure the severity and extent of AD and measures erythema, infiltration, excoriation and lichenification on 4 anatomic regions of the body: head, trunk, upper and lower extremities. The total EASI score ranges from 0 (minimum) to 72 (maximum) points, with the higher scores reflecting the worse severity of AD.
Time frame: Weeks 2, 4, 8, 12, 16, 20, and 24
Percentage of Participants With ≥50% Reduction From Baseline in EASI Score (EASI-50)
The EASI score was used to measure the severity and extent of AD and measures erythema, infiltration, excoriation and lichenification on 4 anatomic regions of the body: head, trunk, upper and lower extremities. The total EASI score ranges from 0 (minimum) to 72 (maximum) points, with the higher scores reflecting the worse severity of AD. EASI-50 responders were the participants who achieved ≥50% overall improvement in EASI score from baseline to the given time point.
Time frame: Weeks 2, 4, 8, 12, 16, 20, and 24
Percentage of Participants With ≥75% Reduction From Baseline in EASI Score (EASI-75)
The EASI score was used to measure the severity and extent of AD and measures erythema, infiltration, excoriation and lichenification on 4 anatomic regions of the body: head, trunk, upper and lower extremities. The total EASI score ranges from 0 (minimum) to 72 (maximum) points, with the higher scores reflecting the worse severity of AD. EASI-75 responders were the participants who achieved ≥75% overall improvement in EASI score from baseline to the given time point.
Time frame: Weeks 2, 4, 8, 12, 16, 20, and 24
Percentage of Participants With ≥90% Reduction From Baseline in EASI Score (EASI-90)
The EASI score was used to measure the severity and extent of AD and measures erythema, infiltration, excoriation and lichenification on 4 anatomic regions of the body: head, trunk, upper and lower extremities. The total EASI score ranges from 0 (minimum) to 72 (maximum) points, with the higher scores reflecting the worse severity of AD. EASI-90 responders were the participants who achieved ≥90% overall improvement in EASI score from baseline to the given time point.
Time frame: Weeks 2, 4, 8, 12, 16, 20, and 24
Percent Change From Baseline in Total Scoring Atopic Dermatitis (SCORAD) Score
The SCORAD index is a clinical tool for assessing the severity of atopic dermatitis. Extent and intensity of eczema as well as subjective signs (insomnia, etc.) are assessed and scored. Total score ranges from 0 (absent disease) to 103 (severe disease).
Time frame: Weeks 2, 4, 8, 12, 16, 20, and 24
Percentage of Participants With ≥50% Reduction From Baseline in SCORAD Score (SCORAD-50)
SCORAD index is a clinical tool for assessing the severity of atopic dermatitis. Extent and intensity of eczema as well as subjective signs insomnia, etc.) were assessed and scored. Total score ranged from 0 (absent disease) to 103 (severe disease). A decrease in score indicated improvement. SCORAD-50 was defined as ≥50% reduction from baseline in SCORAD score.
Time frame: Weeks 2, 4, 8, 12, 16, 20, and 24
Percentage of Participants With Improvement (Reduction) From Baseline of Weekly Average of Daily Peak Pruritus (PP) Numerical Rating Scale (NRS) Score ≥3
Peak Pruritus NRS is an assessment tool used by participants to report intensity of pruritus (itch) during a 24-hour recall period. Participants were asked the following question: For maximum itch intensity: "On a scale of 0 to 10, with 0 being 'no itch' and 10 being the 'worst itch imaginable,' how would you rate your itch at the worst moment during the previous 24 hours?" For post-baseline NRS, the mean weekly NRS was calculated as the prorated average of the reported daily NRS within the week. A decrease in score indicated improvement.
Time frame: Weeks 2, 4, 8, 12, 16, 20, and 24
Percentage of Participants With Improvement (Reduction) From Baseline of Weekly Average of Daily PP NRS Score ≥4
Peak Pruritus NRS is an assessment tool used by participants to report intensity of pruritus (itch) during a 24-hour recall period. Participants were asked the following question: For maximum itch intensity: "On a scale of 0 to 10, with 0 being 'no itch' and 10 being the 'worst itch imaginable,' how would you rate your itch at the worst moment during the previous 24 hours?" For post-baseline NRS, the mean weekly NRS was calculated as the prorated average of the reported daily NRS within the week. A decrease in score indicated improvement.
Time frame: Weeks 2, 4, 8, 12, 16, 20, and 24
Percent Change From Baseline in Weekly Average of Daily PP NRS Score
Peak Pruritus NRS is an assessment tool used by participants to report intensity of pruritus (itch) during a 24-hour recall period. Participants were asked the following question: For maximum itch intensity: "On a scale of 0 to 10, with 0 being 'no itch' and 10 being the 'worst itch imaginable,' how would you rate your itch at the worst moment during the previous 24 hours?" For post-baseline NRS, the mean weekly NRS was calculated as the prorated average of the reported daily NRS within the week. A decrease in score indicated improvement.
Time frame: Weeks 2, 4, 8, 12, 16, 20, and 24
Change From Baseline in Weekly Average of Daily PP NRS Score
Peak Pruritus NRS is an assessment tool used by subjects to report intensity of pruritus (itch) during a 24-hour recall period. Participants were asked the following question: For maximum itch intensity: "On a scale of 0 to 10, with 0 being 'no itch' and 10 being the 'worst itch imaginable,' how would you rate your itch at the worst moment during the previous 24 hours?" For post-baseline NRS, the mean weekly NRS was calculated as the prorated average of the reported daily NRS within the week. A decrease in score indicated improvement.
Time frame: Weeks 2, 4, 8, 12, 16, 20, and 24
Percent Change From Baseline in Percent Body Surface Area (BSA)
BSA affected by AD was assessed for each section of the body using the rule of nines (the possible highest score for each region was: head and neck \[9%\], interior trunk \[18%\], back \[18%\], upper limbs \[18%\], lower limbs \[36%\], and genitals \[1%\]). BSA was reported as a percentage of all major body sections combined.
Time frame: Weeks 2, 4, 8, 12, 16, 20, and 24
Change From Baseline in Health-related Quality of Life (QOL) as Measured by Dermatology Life Quality Index (DLQI; Age ≥16) Score
DLQI is a 10-item, validated questionnaire to assess the impact of AD disease symptoms and treatment on QOL; over the past week, with an overall scoring of 0 (no effect on QoL) to 30 (extremely large effect on QoL). A decrease in score indicated improvement.
Time frame: Weeks 2, 4, 8, 12, 16, 20, and 24
Change From Baseline in Health-related QOL as Measured by Children's Dermatology Life Quality Index (CDLQI; Age <16) Score
CDLQI is a 10-item, validated questionnaire to assess the impact of AD disease symptoms and treatment on quality of life (QOL); over the past week, with an overall scoring of 0 (no effect on QoL) to 30 (extremely large effect on QoL) in children. A decrease in score indicated improvement.
Time frame: Weeks 2, 4, 8, 12, 16, 20, and 24
Change From Baseline in Patient Oriented Eczema Measure (POEM) Total Score
POEM is a 7-item questionnaire that assesses disease symptoms (dryness, itching, flaking, cracking, sleep loss, bleeding and weeping) with a scoring system of 0 (absent disease) to 28 (severe disease) (Higher score indicative of more severe symptoms). Total score was an average of the disease symptoms assessed. A decrease in score indicated improvement.
Time frame: Weeks 2, 4, 8, 12, 16, 20, and 24
Change From Baseline in Hospital Anxiety and Depression Scale (HADS) Total Score
The Hospital Anxiety and Depression Scale (HADS) is a screening tool designed to assess anxiety and depression. The scale consists of 14 items, divided into two subscales: Anxiety (HADS-A): 7 items; Depression (HADS-D): 7 items. The range of the total score is 0-42 (sum of HADS-A and HADS-D), with higher score indicating more severe overall psychological distress. The two subscales can be reported separately, each with a score range of 0-21, with higher score indicating more severe symptoms of anxiety or depression. A decrease in either the total score or a subscale score indicates improvement.
Time frame: Weeks 2, 4, 8, 12, 16, 20, and 24
Change From Baseline in Skin Pain NRS (SP NRS) Score
SP NRS Scale is an assessment tool used to report the intensity of a participant's pain. Participants selected the number between 0 and 10 that fit best to their worst pain intensity over the past 24 hours (0 = no pain and 10 = the worst pain imaginable). A decrease in score indicated improvement.
Time frame: Weeks 2, 4, 8, 12, 16, 20, and 24
Change From Baseline in Weekly Average Sleep Quality NRS Score
Sleep Quality NRS is an 11-point scale (0 to 10) in which 0 indicated worst possible sleep while 10 indicated best possible sleep. An increase in score indicated improvement.
Time frame: Weeks 2, 4, 8, 12, 16, 20, and 24
Percentage of Participants With Patient Global Impression of Disease (PGID) Response as No Symptoms
PGID is a single 1-item questionnaire designed to assess participant's overall impression of disease severity during the past 7 days with a 5-level scale of no symptoms, mild, moderate, severe or very severe. Data are reported for the percentage of participants with a PGID response of "No symptoms" at the specified timepoints.
Time frame: Weeks 2, 4, 8, 12, 16, 20, and 24
Percentage of Participants With PGID Response as No Symptoms or Mild Symptoms
PGID is a single 1-item questionnaire designed to assess participant's overall impression of disease severity during the past 7 days with a 5-level scale of no symptoms, mild, moderate, severe or very severe. Data are reported for the percentage of participants with a PGID response of "No symptoms" or "Mild symptoms" at the specified timepoints.
Time frame: Weeks 2, 4, 8, 12, 16, 20, and 24
Percentage of Participants Who Rated Their Eczema Symptoms in the Patient Global Impression of Change (PGIC) as "Much Better"
The PGIC is a single-item questionnaire designed to assess the participant's overall sense of whether there has been a change in eczema symptoms since starting treatment as rated on a 7-point Likert scale anchored by (1) "much better" to (7) "much worse", with (4) = "no change". Data are reported for the percentage of participants who rated their eczema symptoms as "Much better" at the specified timepoints.
Time frame: Weeks 2, 4, 8, 12, 16, 20, and 24
Percentage of Participants Who Rated Their Eczema Symptoms in the PGIC as "Moderately Better"
The PGIC is a single-item questionnaire designed to assess the participant's overall sense of whether there has been a change in eczema symptoms since starting treatment as rated on a 7-point Likert scale anchored by (1) "much better" to (7) "much worse", with (4) = "no change". Data are reported for the percentage of participants who rated their eczema symptoms as "Moderately better" at the specified timepoints.
Time frame: Weeks 2, 4, 8, 12, 16, 20, and 24
Number of Participants With Non-herpetic Skin Infection Treatment-emergent Adverse Events (TEAEs)
A TEAE is any untoward medical occurrence in a participant administered a pharmaceutical product, which does not necessarily have a causal relationship with this treatment. Data are reported for the number of participants with non-herpetic skin infection TEAEs. A summary of all serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Events module.
Time frame: Day 1 through Week 24
Change From Baseline in Total Immunoglobulin (E) IgE
Serum samples were collected to measure concentrations of IgE.
Time frame: Weeks 4, 12 and 24
Percent Change From Baseline in Total IgE
Serum samples were collected to measure concentrations of IgE.
Time frame: Weeks 4, 12 and 24
Trough Concentration of Functional Dupilumab in Serum
Adolescents and adults received 1 of 2 dose regimens based on age and body weight. The trough concentration of functional dupilumab in serum for the 2 dose regimens at the specified time points are presented. Participants treated and had at least one evaluable post-first-dose concentration measurement.
Time frame: Week 12 and Week 24
| Milestone | Dupilumab |
|---|---|
| Started | 124 |
| Received at least 1 dose of dupilumab | 124 |
| Completed | 120 |
| Not completed | 4 |
| Withdrew: Lost to follow-up | 3 |
| Withdrew: Withdrawal by subject | 1 |
IGA is an assessment scale used to determine severity of atopic dermatitis (AD) and clinical response to treatment on a 5-point scale (0 = clear; 1 = almost clear; 2 = mild; 3 = moderate; 4 = severe) based on erythema and papulation/infiltration. Therapeutic response was an IGA score of 0 (clear) or 1 (almost clear). Percentage of participants with IGA "0" or "1" are reported at each visit.
| percentage of participants | Dupilumab |
|---|---|
| Week 2 | 0.9 |
| Week 4 | 6.8 |
| Week 8 | 15.9 |
| Week 12 | 25.9 |
| Week 16 | 35.2 |
| Week 20 | 45.4 |
| Week 24 | 44.0 |
The Eczema Area and Severity Index (EASI) score was used to measure the severity and extent of AD and measures erythema, infiltration, excoriation and lichenification on 4 anatomic regions of the body: head, trunk, upper and lower extremities. The total EASI score ranges from 0 (minimum) to 72 (maximum) points, with the higher scores reflecting the worse severity of AD.
| percent change | Dupilumab |
|---|---|
| Week 2 | -25.929 ± 29.782 |
| Week 4 | -46.092 ± 30.000 |
| Week 8 | -67.270 ± 25.689 |
| Week 12 | -70.999 ± 25.798 |
| Week 16 | -73.276 ± 32.975 |
| Week 20 | -79.185 ± 23.612 |
| Week 24 | -79.941 ± 25.634 |
The Eczema Area and Severity Index (EASI) score was used to measure the severity and extent of AD and measures erythema, infiltration, excoriation and lichenification on 4 anatomic regions of the body: head, trunk, upper and lower extremities. The total EASI score ranges from 0 (minimum) to 72 (maximum) points, with the higher scores reflecting the worse severity of AD.
| score on scale | Dupilumab |
|---|---|
| Week 2 | -7.105 ± 7.504 |
| Week 4 | -12.097 ± 9.338 |
| Week 8 | -17.779 ± 10.178 |
| Week 12 | -18.475 ± 9.768 |
| Week 16 | -19.460 ± 11.663 |
| Week 20 | -20.985 ± 11.249 |
| Week 24 | -20.980 ± 11.071 |
The EASI score was used to measure the severity and extent of AD and measures erythema, infiltration, excoriation and lichenification on 4 anatomic regions of the body: head, trunk, upper and lower extremities. The total EASI score ranges from 0 (minimum) to 72 (maximum) points, with the higher scores reflecting the worse severity of AD. EASI-50 responders were the participants who achieved ≥50% overall improvement in EASI score from baseline to the given time point.
| percentage of participants | Dupilumab |
|---|---|
| Week 2 | 17.2 |
| Week 4 | 47.9 |
| Week 8 | 77.9 |
| Week 12 | 84.3 |
| Week 16 | 84.3 |
| Week 20 | 89.7 |
| Week 24 | 89.0 |
The EASI score was used to measure the severity and extent of AD and measures erythema, infiltration, excoriation and lichenification on 4 anatomic regions of the body: head, trunk, upper and lower extremities. The total EASI score ranges from 0 (minimum) to 72 (maximum) points, with the higher scores reflecting the worse severity of AD. EASI-75 responders were the participants who achieved ≥75% overall improvement in EASI score from baseline to the given time point.
| percentage of participants | Dupilumab |
|---|---|
| Week 2 | 3.4 |
| Week 4 | 23.1 |
| Week 8 | 50.4 |
| Week 12 | 56.5 |
| Week 16 | 63.9 |
| Week 20 | 74.2 |
| Week 24 | 76.0 |
The EASI score was used to measure the severity and extent of AD and measures erythema, infiltration, excoriation and lichenification on 4 anatomic regions of the body: head, trunk, upper and lower extremities. The total EASI score ranges from 0 (minimum) to 72 (maximum) points, with the higher scores reflecting the worse severity of AD. EASI-90 responders were the participants who achieved ≥90% overall improvement in EASI score from baseline to the given time point.
| percentage of participants | Dupilumab |
|---|---|
| Week 2 | 0.9 |
| Week 4 | 5.1 |
| Week 8 | 15.0 |
| Week 12 | 27.8 |
| Week 16 | 38.9 |
| Week 20 | 41.2 |
| Week 24 | 42.0 |
The SCORAD index is a clinical tool for assessing the severity of atopic dermatitis. Extent and intensity of eczema as well as subjective signs (insomnia, etc.) are assessed and scored. Total score ranges from 0 (absent disease) to 103 (severe disease).
| percent change | Dupilumab |
|---|---|
| Week 2 | -18.5 ± 17.8 |
| Week 4 | -30.2 ± 22.6 |
| Week 8 | -44.4 ± 22.8 |
| Week 12 | -50.5 ± 23.0 |
| Week 16 | -53.2 ± 26.0 |
| Week 20 | -55.6 ± 24.3 |
| Week 24 | -59.3 ± 26.0 |
SCORAD index is a clinical tool for assessing the severity of atopic dermatitis. Extent and intensity of eczema as well as subjective signs insomnia, etc.) were assessed and scored. Total score ranged from 0 (absent disease) to 103 (severe disease). A decrease in score indicated improvement. SCORAD-50 was defined as ≥50% reduction from baseline in SCORAD score.
| percentage of participants | Dupilumab |
|---|---|
| Week 2 | 9.1 |
| Week 4 | 16.2 |
| Week 8 | 39.3 |
| Week 12 | 52.9 |
| Week 16 | 59.8 |
| Week 20 | 68.1 |
| Week 24 | 70.2 |
Peak Pruritus NRS is an assessment tool used by participants to report intensity of pruritus (itch) during a 24-hour recall period. Participants were asked the following question: For maximum itch intensity: "On a scale of 0 to 10, with 0 being 'no itch' and 10 being the 'worst itch imaginable,' how would you rate your itch at the worst moment during the previous 24 hours?" For post-baseline NRS, the mean weekly NRS was calculated as the prorated average of the reported daily NRS within the week. A decrease in score indicated improvement.
| percentage of participants | Dupilumab |
|---|---|
| Week 2 | 14.3 |
| Week 4 | 31.6 |
| Week 8 | 48.2 |
| Week 12 | 54.6 |
| Week 16 | 64.8 |
| Week 20 | 68.0 |
| Week 24 | 65.6 |
Peak Pruritus NRS is an assessment tool used by participants to report intensity of pruritus (itch) during a 24-hour recall period. Participants were asked the following question: For maximum itch intensity: "On a scale of 0 to 10, with 0 being 'no itch' and 10 being the 'worst itch imaginable,' how would you rate your itch at the worst moment during the previous 24 hours?" For post-baseline NRS, the mean weekly NRS was calculated as the prorated average of the reported daily NRS within the week. A decrease in score indicated improvement.
| percentage of participants | Dupilumab |
|---|---|
| Week 2 | 8.4 |
| Week 4 | 19.7 |
| Week 8 | 32.5 |
| Week 12 | 38.9 |
| Week 16 | 44.4 |
| Week 20 | 47.6 |
| Week 24 | 52.7 |
Peak Pruritus NRS is an assessment tool used by participants to report intensity of pruritus (itch) during a 24-hour recall period. Participants were asked the following question: For maximum itch intensity: "On a scale of 0 to 10, with 0 being 'no itch' and 10 being the 'worst itch imaginable,' how would you rate your itch at the worst moment during the previous 24 hours?" For post-baseline NRS, the mean weekly NRS was calculated as the prorated average of the reported daily NRS within the week. A decrease in score indicated improvement.
| Percentage of change | Dupilumab |
|---|---|
| Week 2 | -16.253 ± 25.364 |
| Week 4 | -28.672 ± 28.427 |
| Week 8 | -41.010 ± 33.346 |
| Week 12 | -45.944 ± 31.358 |
| Week 16 | -52.706 ± 30.812 |
| Week 20 | -54.138 ± 28.698 |
| Week 24 | -56.337 ± 31.036 |
Peak Pruritus NRS is an assessment tool used by subjects to report intensity of pruritus (itch) during a 24-hour recall period. Participants were asked the following question: For maximum itch intensity: "On a scale of 0 to 10, with 0 being 'no itch' and 10 being the 'worst itch imaginable,' how would you rate your itch at the worst moment during the previous 24 hours?" For post-baseline NRS, the mean weekly NRS was calculated as the prorated average of the reported daily NRS within the week. A decrease in score indicated improvement.
| score on a scale | Dupilumab |
|---|---|
| Week 2 | -1.234 ± 1.663 |
| Week 4 | -2.058 ± 2.021 |
| Week 8 | -2.939 ± 2.379 |
| Week 12 | -3.237 ± 2.266 |
| Week 16 | -3.741 ± 2.369 |
| Week 20 | -3.823 ± 2.184 |
| Week 24 | -3.981 ± 2.326 |
BSA affected by AD was assessed for each section of the body using the rule of nines (the possible highest score for each region was: head and neck \[9%\], interior trunk \[18%\], back \[18%\], upper limbs \[18%\], lower limbs \[36%\], and genitals \[1%\]). BSA was reported as a percentage of all major body sections combined.
| Percentage of change | Dupilumab |
|---|---|
| Week 2 | -17.91 ± 24.92 |
| Week 4 | -31.07 ± 31.06 |
| Week 8 | -53.09 ± 30.67 |
| Week 12 | -60.04 ± 31.45 |
| Week 16 | -64.65 ± 32.79 |
| Week 20 | -71.03 ± 28.50 |
| Week 24 | -73.69 ± 28.31 |
DLQI is a 10-item, validated questionnaire to assess the impact of AD disease symptoms and treatment on QOL; over the past week, with an overall scoring of 0 (no effect on QoL) to 30 (extremely large effect on QoL). A decrease in score indicated improvement.
| score on a scale | Dupilumab |
|---|---|
| Week 2 | -4.5 ± 5.4 |
| Week 4 | -5.6 ± 7.1 |
| Week 8 | -6.7 ± 6.5 |
| Week 12 | -7.6 ± 5.7 |
| Week 16 | -7.6 ± 6.7 |
| Week 20 | -8.5 ± 6.5 |
| Week 24 | -8.3 ± 7.1 |
CDLQI is a 10-item, validated questionnaire to assess the impact of AD disease symptoms and treatment on quality of life (QOL); over the past week, with an overall scoring of 0 (no effect on QoL) to 30 (extremely large effect on QoL) in children. A decrease in score indicated improvement.
| score on a scale | Dupilumab |
|---|---|
| Week 2 | -4.2 ± 5.4 |
| Week 4 | -5.0 ± 5.2 |
| Week 8 | -5.1 ± 4.2 |
| Week 12 | -6.3 ± 7.0 |
| Week 16 | -8.5 ± 5.6 |
| Week 20 | -8.6 ± 5.4 |
| Week 24 | -7.8 ± 5.5 |
POEM is a 7-item questionnaire that assesses disease symptoms (dryness, itching, flaking, cracking, sleep loss, bleeding and weeping) with a scoring system of 0 (absent disease) to 28 (severe disease) (Higher score indicative of more severe symptoms). Total score was an average of the disease symptoms assessed. A decrease in score indicated improvement.
| score on a scale | Dupilumab |
|---|---|
| Week 2 | -5.6 ± 6.0 |
| Week 4 | -8.3 ± 6.6 |
| Week 8 | -10.3 ± 6.5 |
| Week 12 | -11.0 ± 6.3 |
| Week 16 | -11.2 ± 7.0 |
| Week 20 | -11.3 ± 7.0 |
| Week 24 | -11.5 ± 7.0 |
The Hospital Anxiety and Depression Scale (HADS) is a screening tool designed to assess anxiety and depression. The scale consists of 14 items, divided into two subscales: Anxiety (HADS-A): 7 items; Depression (HADS-D): 7 items. The range of the total score is 0-42 (sum of HADS-A and HADS-D), with higher score indicating more severe overall psychological distress. The two subscales can be reported separately, each with a score range of 0-21, with higher score indicating more severe symptoms of anxiety or depression. A decrease in either the total score or a subscale score indicates improvement.
| score on a scale | Dupilumab |
|---|---|
| Week 2 | -1.8 ± 5.0 |
| Week 4 | -2.3 ± 5.5 |
| Week 8 | -2.8 ± 5.6 |
| Week 12 | -3.7 ± 5.5 |
| Week 16 | -3.4 ± 5.8 |
| Week 20 | -3.4 ± 6.1 |
| Week 24 | -3.2 ± 6.3 |
SP NRS Scale is an assessment tool used to report the intensity of a participant's pain. Participants selected the number between 0 and 10 that fit best to their worst pain intensity over the past 24 hours (0 = no pain and 10 = the worst pain imaginable). A decrease in score indicated improvement.
| score on a scale | Dupilumab |
|---|---|
| Week 2 | -2.3 ± 3.6 |
| Week 4 | -2.6 ± 4.0 |
| Week 8 | -3.2 ± 3.5 |
| Week 12 | -3.3 ± 3.5 |
| Week 16 | -3.0 ± 3.4 |
| Week 20 | -3.0 ± 3.2 |
| Week 24 | -2.9 ± 3.5 |
Sleep Quality NRS is an 11-point scale (0 to 10) in which 0 indicated worst possible sleep while 10 indicated best possible sleep. An increase in score indicated improvement.
| score on a scale | Dupilumab |
|---|---|
| Week 2 | 0.473 ± 1.565 |
| Week 4 | 0.910 ± 1.937 |
| Week 8 | 1.204 ± 2.459 |
| Week 12 | 1.281 ± 2.173 |
| Week 16 | 1.239 ± 2.097 |
| Week 20 | 1.045 ± 2.631 |
| Week 24 | 1.210 ± 2.696 |
PGID is a single 1-item questionnaire designed to assess participant's overall impression of disease severity during the past 7 days with a 5-level scale of no symptoms, mild, moderate, severe or very severe. Data are reported for the percentage of participants with a PGID response of "No symptoms" at the specified timepoints.
| percentage of participants | Dupilumab |
|---|---|
| Week 2 | 4.0 |
| Week 4 | 4.0 |
| Week 8 | 14.6 |
| Week 12 | 10.0 |
| Week 16 | 12.0 |
| Week 20 | 14.3 |
| Week 24 | 23.8 |
PGID is a single 1-item questionnaire designed to assess participant's overall impression of disease severity during the past 7 days with a 5-level scale of no symptoms, mild, moderate, severe or very severe. Data are reported for the percentage of participants with a PGID response of "No symptoms" or "Mild symptoms" at the specified timepoints.
| percentage of participants | Dupilumab |
|---|---|
| Week 2 | 26.7 |
| Week 4 | 46.0 |
| Week 8 | 59.4 |
| Week 12 | 65.6 |
| Week 16 | 68.5 |
| Week 20 | 64.3 |
| Week 24 | 67.5 |
The PGIC is a single-item questionnaire designed to assess the participant's overall sense of whether there has been a change in eczema symptoms since starting treatment as rated on a 7-point Likert scale anchored by (1) "much better" to (7) "much worse", with (4) = "no change". Data are reported for the percentage of participants who rated their eczema symptoms as "Much better" at the specified timepoints.
| percentage of participants | Dupilumab |
|---|---|
| Week 2 | 15.8 |
| Week 4 | 23.7 |
| Week 8 | 44.1 |
| Week 12 | 45.6 |
| Week 16 | 50.5 |
| Week 20 | 55.2 |
| Week 24 | 53.8 |
The PGIC is a single-item questionnaire designed to assess the participant's overall sense of whether there has been a change in eczema symptoms since starting treatment as rated on a 7-point Likert scale anchored by (1) "much better" to (7) "much worse", with (4) = "no change". Data are reported for the percentage of participants who rated their eczema symptoms as "Moderately better" at the specified timepoints.
| percentage of participants | Dupilumab |
|---|---|
| Week 2 | 14.0 |
| Week 4 | 27.2 |
| Week 8 | 23.4 |
| Week 12 | 28.2 |
| Week 16 | 27.6 |
| Week 20 | 25.0 |
| Week 24 | 23.1 |
A TEAE is any untoward medical occurrence in a participant administered a pharmaceutical product, which does not necessarily have a causal relationship with this treatment. Data are reported for the number of participants with non-herpetic skin infection TEAEs. A summary of all serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Events module.
| Participants | Dupilumab |
|---|---|
| Number of Participants With Non-herpetic Skin Infection Treatment-emergent Adverse Events (TEAEs) | 1 |
Serum samples were collected to measure concentrations of IgE.
| kU/L | Dupilumab |
|---|---|
| Week 4 | -493.277 ± 1964.991 |
| Week 12 | -2284.021 ± 5579.402 |
| Week 24 | -3177.471 ± 6959.014 |
Serum samples were collected to measure concentrations of IgE.
| percent change | Dupilumab |
|---|---|
| Week 4 | -6.277 ± 62.301 |
| Week 12 | -39.703 ± 25.145 |
| Week 24 | -50.375 ± 69.291 |
Adolescents and adults received 1 of 2 dose regimens based on age and body weight. The trough concentration of functional dupilumab in serum for the 2 dose regimens at the specified time points are presented. Participants treated and had at least one evaluable post-first-dose concentration measurement.
| mg/L | Dupilumab |
|---|---|
| Dose Regimen 1: Week 12 | 40.8 ± 28.7 |
| Dose Regimen 2: Week 12 | 43.9 ± 28.4 |
| Dose Regimen 1: Week 24 | 43.9 ± 28.0 |
| Dose Regimen 2: Week 24 | 49.6 ± 33.4 |
The EASI score was used to measure the severity and extent of atopic dermatitis (AD) and measures erythema, infiltration, excoriation and lichenification on 4 anatomic regions of the body: head, trunk, upper and lower extremities. The total EASI score ranges from 0 (minimum) to 72 (maximum) points, with the higher scores reflecting the worse severity of AD. EASI-75 responders were the participants who achieved ≥75% overall improvement in EASI score from baseline to Week 24.
| percentage of participants | Dupilumab |
|---|---|
| Percentage of Participants With ≥75% Reduction From Baseline in Eczema Area and Severity Index (EASI) Score (EASI-75) | 76.0 (66.43 to 83.98) |
Collected over Day 1 through Week 24. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Dupilumab | 1/124 (0.8%) | 7/124 (5.6%) | 0/124 (0%) |
| Event | Dupilumab |
|---|---|
| Septic shockInfections and infestations | 1/124 |
| SinusitisInfections and infestations | 1/124 |
| EncephalopathyNervous system disorders | 1/124 |
| SeizureNervous system disorders | 1/124 |
| IntussusceptionGastrointestinal disorders | 1/124 |
| Bile duct stoneHepatobiliary disorders | 1/124 |
| Drug hypersensitivityImmune system disorders | 1/124 |
| ConcussionInjury, poisoning and procedural complications | 1/124 |
| Blood pressure increasedInvestigations | 1/124 |
| MyalgiaMusculoskeletal and connective tissue disorders | 1/124 |
Full Analysis Set (FAS): All participants who were enrolled in the study and had at least 1 post-baseline efficacy assessment.
| Age, Continuous(years) | Dupilumab |
|---|---|
| Mean | 37.6 ± 16.9 |
| Sex: Female, Male(Participants) | Dupilumab |
|---|---|
| Female | 56 |
| Male | 64 |
| Ethnicity (NIH/OMB)(Participants) | Dupilumab |
|---|---|
| Hispanic or Latino | 17 |
| Not Hispanic or Latino | 100 |
| Unknown or Not Reported | 3 |
| Race/Ethnicity, Customized(Participants) | Dupilumab |
|---|---|
| Race — White | 3 |
| Race — Black or African American | 98 |
| Race — Asian | 13 |
| Race — American Indian or Alaska Native | 3 |
| Race — Native Hawaiian or Other Pacific Islander | 0 |
| Race — Other | 3 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — All Individual Patient Data (IPD) that underlie publicly available results will be considered for sharing.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code
Time frame: When Regeneron has received marketing authorization from major health authorities (e.g., FDA, European Medicines Agency (EMA), Pharmaceuticals and Medical Devices Agency (PMDA), etc.) for the product and indication, has made results publicly available (e.g., scientific publication, scientific conference, clinical trial registry), has the legal authority to share the data, and has ensured the ability to protect participant privacy.
Access criteria: Qualified researchers can submit a proposal for access to individual patient or aggregate level data from a Regeneron-sponsored clinical trial through Vivli. Regeneron's Independent Research Request Evaluation Criteria can be found at: https://www.regeneron.com/sites/default/files/Regeneron-External-Data-Sharing-Policy-and-Independent-Research-Request-Evaluation-Criteria.pdf
Data sharing details ↗ · vivli.org
Ran from Jan 2023 to primary completion in Nov 2024, 22 months.
Results were first posted in Jan 2026, 1 year 1 month after primary completion.
Of 45 phase 4 interventional studies under Dermatitis, Atopic, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 41. This study's 22 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Dupilumab